Form 4: TELA Bio Director Rocchio Granted Equity Awards

TELA Bio, Inc. Director Betty Jo Rocchio received grants of restricted stock units and stock options as part of her compensation.

Summary

• Director Betty Jo Rocchio of TELA Bio, Inc. was granted equity awards on October 9, 2025.
• The awards include 11,925 restricted stock units (RSUs) and 17,550 stock options.
• The restricted stock units were granted at a price of $0 and will vest in three equal annual installments beginning on October 9, 2026.
• The stock options have an exercise price of $1.48 and will vest in 36 equal monthly installments on each monthly anniversary of October 9, 2025.
• Both equity awards are subject to the reporting person's continued service through their respective vesting dates.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders but does not represent a significant new development beyond standard compensation practices.

Positives

• Grant of 11,925 restricted stock units (RSUs) to Director Betty Jo Rocchio, aligning her interests with long-term shareholder value.
• Grant of 17,550 stock options with an exercise price of $1.48, providing an incentive for future stock price appreciation.
• Equity awards are tied to continued service, promoting retention of key leadership and sustained engagement.

Risks

• Vesting of both restricted stock units and stock options is contingent upon the reporting person's continued service, meaning unvested awards could be forfeited if service ceases.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend into future years (2026 for RSUs, monthly through 2028 for options), indicating an expectation of continued service from the director and a long-term alignment of interests.

Industry Context

The grant of equity awards to directors is a common practice in the biotechnology and medical device industry, aiming to align the interests of board members with those of shareholders and incentivize long-term performance and retention.

Comparison to Industry Standards

• Equity compensation for directors, including restricted stock units and stock options, is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to attract and retain qualified board members.
• The specific vesting schedules (annual for RSUs, monthly for options over three years) are typical for director compensation plans, designed to encourage sustained engagement and long-term value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.

Next Steps

• First annual vesting of restricted stock units on October 9, 2026.
• Ongoing monthly vesting of stock options starting October 9, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis or warrant a change in an existing position. It's a standard governance event.

Keywords

TELA Bio, equity grant, director compensation, stock options, restricted stock units, insider transaction, Form 4